Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554488 | 1.00 | ACACB (0.43) | ACACBGRM2FFAR1FFAR4AR | |
| SCHEMBL20943271 | 0.86 | ACACB (0.41) | ACACBGRM2FFAR1FFAR4AR | |
| SCHEMBL14313759 | 0.85 | ALDH1A1 (0.46) | ACACBGRM2ARNAMPTALDH1A1 | |
| SCHEMBL30404220 | 0.80 | GRM2 (0.38) | ACACBGRM2FFAR1FFAR4AR | |
| SCHEMBL27718312 | 0.78 | TSHR (0.51) | NAMPTALDH1A1MAPTMET | |
| SCHEMBL9519051 | 0.78 | MYC (0.40) | GRM2ALDH1A1MAPTKDM1AUSP14 | |
| SCHEMBL25399532 | 0.78 | PDE3B (0.38) | GRM2ALDH1A1KDM1AUSP14PDE4B | |
| SCHEMBL14109903 | 0.77 | CYP4F2 (0.54) | ACACBFFAR1FFAR4ALDH1A1MAPT | |
| SCHEMBL20943263 | 0.77 | ALDH1A1 (0.54) | FFAR1ALDH1A1MAPT | |
| SCHEMBL20719611 | 0.77 | RAD52 (0.38) | ALDH1A1MAPTMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3447058-B1 | NOVEL BROAD-SPECTRUM BETA-LACTAMASE INHIBITOR | WUHAN VISION PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-3476829-B1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | UNIV FUDAN (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20200239411-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | UNIV FUDAN (CN) | 2020-07-30 | — | — | US | disclosed |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-05-12 | — | — | US | disclosed |
| US-10479805-B2 | Beta-lactamase inhibitor | WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-11-19 | — | — | US | disclosed |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | FUDAN UNIVERSITY (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3476829-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | Fudan University (CN) | 2019-05-01 | — | — | EP | disclosed |
| US-20190048027-A1 | BETA-LACTAMASE INHIBITOR | WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048027-A1 | BETA-LACTAMASE INHIBITOR | ALPI, MGAM, LCT | ACACB 984/4885GRM2 4631/4885FFAR1 4427/4885 |
| US-20200239411-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | ACACB 1389/4885GRM2 3382/4885FFAR1 849/4885 |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | ACACB 1598/4885GRM2 3595/4885FFAR1 702/4885 |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | ACACB 1598/4885GRM2 3595/4885FFAR1 702/4885 |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | ACACB 1389/4885GRM2 3382/4885FFAR1 849/4885 |
| US-10479805-B2 | Beta-lactamase inhibitor | ALPI, MGAM, LCT | ACACB 984/4885GRM2 4631/4885FFAR1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.